For decades, physicians have watched cardiovascular disease arrive in type 1 diabetes patients whose blood sugar numbers appeared controlled — a quiet failure of the tools meant to protect them. A large European study, drawing on data from nearly 44,000 patients, now proposes a more discerning lens: one that reads not just individual biomarkers, but the relationship between a patient's body composition and their underlying metabolic signals. Where standard risk calculators see reassurance, this phenotype-based model sees discordance — and in that discordance, it finds danger that conventional
New model improves cardiovascular risk prediction in type 1 diabetes
A mismatch between weight and biomarkers becomes diagnostic information itself
Mark
So the study found that most type 1 diabetes patients fall into a high-risk category that existing tools don't catch. How does that actually change what a doctor does?
Mimi
It gives them a way to identify which patients need closer cardiovascular monitoring and earlier intervention. Instead of treating everyone the same or relying on blood sugar numbers alone, they can see that someone's weight and biomarkers are telling different stories—and that mismatch itself is a warning sign.
Luke
But the improvements weren't universal, right? The model helped predict heart events in men in some cohorts but not others. And for retinopathy, it worked in different groups depending on which cohort you look at. That's not a slam dunk.
Mimi
No, it's not. But that's actually honest reporting. The model does better in some populations and for some outcomes. The net benefit analysis shows real gains—avoiding thousands of unnecessary interventions while correctly identifying people who need treatment.
Mark
What about the fact that this is cross-sectional data? Does that undermine the findings?
Luke
It's a legitimate concern. You're looking at a moment in time, not watching how people actually change over years. The authors acknowledge this and say longitudinal studies are needed. But they also note that some recent evidence suggests cross-sectional data can predict outcomes as well as longitudinal data, and it's easier to get in practice.
Mimi
The bigger point is that the model uses data doctors already have. It doesn't require new tests or new equipment. If it helps even a subset of patients get identified earlier, that's valuable.
Mark
And the hyperglycemic phenotype showing up in 55 to 76 percent of type 1 diabetes patients—that's the real finding, isn't it? That's what was invisible before.
Luke
That's the observation, yes. Whether that phenotype is actually causing the cardiovascular risk or just correlating with it—that's still an open question. The study shows association, not causation.
Mimi
True. But for a clinician trying to decide who to monitor closely, the association is enough to act on. You don't need to understand every mechanism to use a tool that works.
Mark
So what happens next?
Mimi
The model needs validation in other populations, particularly outside Europe. And researchers need to follow patients over time to see if these risk profiles stay stable or shift. That will tell us whether this approach actually prevents complications long-term.
O Pulso
- Standard cardiovascular risk tools systematically underestimate danger in type 1 diabetes patients, leaving a majority — between 55 and 76 percent — carrying a high-risk hyperglycemic profile that goes undetected.
- The gap between what a patient's weight suggests and what their biomarkers reveal is not noise; it is the signal, and ignoring it has real consequences for who receives timely intervention.
- Researchers tested a phenotype-driven model against SCORE2, the European cardiology standard, and found meaningful improvements in predicting heart events and retinopathy — though gains varied by sex and cohort, underscoring the complexity of the disease.
- Decision curve analysis revealed the model's practical power: in one male subgroup, it correctly identified additional high-risk patients while sparing thousands from unnecessary treatment per 10,000 people screened.
- The tool demands nothing new from clinicians — only the routine measurements already collected — and exists as a digital application ready for integration into electronic health records.
- Cross-sectional data and a European-only sample leave questions about long-term stability and global applicability open, making validation studies the critical next step.
For decades, physicians have watched cardiovascular disease arrive in type 1 diabetes patients whose blood sugar numbers appeared controlled — a quiet failure of the tools meant to protect them. A large European study, drawing on data from nearly 44,000 patients, now proposes a more discerning lens: one that reads not just individual biomarkers, but the relationship between a patient's body composition and their underlying metabolic signals. Where standard risk calculators see reassurance, this phenotype-based model sees discordance — and in that discordance, it finds danger that conventional medicine has long overlooked.
Doctors have long faced a troubling paradox in type 1 diabetes: blood sugar levels appear managed, yet heart disease arrives anyway. A major European study, published in Nature Communications and drawing on roughly 44,000 patients across three cohorts, now offers a framework for seeing past that blind spot.
The model works by examining not just individual biomarkers — blood sugar, cholesterol, blood pressure, BMI — but the relationship between them. When a patient's body weight and their cardiometabolic markers tell conflicting stories, that discordance itself becomes diagnostic. In the general population, a high-risk discordant hyperglycemic profile appears in about 2.5 percent of people. In type 1 diabetes patients, it appeared in 55 to 76 percent — a finding that reframes how fundamentally different this population's cardiovascular risk landscape truly is.
When tested against SCORE2, the standard European cardiovascular risk calculator, the new model improved predictions — selectively but meaningfully. In some cohorts it enhanced heart event prediction in men; in others it extended to women and to complications like diabetic retinopathy. A decision curve analysis made the practical stakes concrete: at a 10 percent risk threshold, the model identified additional patients who genuinely needed intervention while sparing thousands from unnecessary treatment per 10,000 screened.
The approach requires no specialized testing — only the routine clinical measurements physicians already collect, plus a waist-to-hip ratio that takes seconds to obtain. A digital application already exists that could integrate directly into electronic health records.
Limitations are real: the study captures a moment in time rather than tracking patients across years, and European data constrains how broadly the findings apply. But the core insight holds — type 1 diabetes demands its own cardiovascular risk framework, and a more granular model of patient phenotypes may finally give clinicians the precision to intervene before complications arrive.
Doctors have long struggled to predict which people with type 1 diabetes will develop heart disease. Blood sugar control looks good on paper—the numbers are in range—yet cardiovascular complications still arrive. A large European study now offers a way to see past that blind spot, using a framework that sorts patients into risk categories based not just on weight, but on how their weight aligns with their underlying metabolic markers.
The research, published in Nature Communications, analyzed data from roughly 44,000 type 1 diabetes patients across three European cohorts. The team applied a phenotype-driven risk model—a tool originally developed to identify hidden cardiovascular danger in the general population—to see if it could work better in diabetes. The model assigns patients to profiles based on the match between their body mass index and their cardiometabolic biomarkers: blood sugar, cholesterol, blood pressure, and other markers. When those measures align, the risk profile is one thing. When they diverge—when someone's weight suggests lower risk but their biomarkers tell a different story—that discordance itself becomes diagnostic information.
What emerged was striking. In the original general population study, a discordant hyperglycemic profile showed up in about 2.5 percent of people. In the type 1 diabetes population, it appeared in 55 to 76 percent. This phenotype, marked by elevated blood sugar despite treatment, represents a fundamentally different risk landscape than what conventional tools assume. Patients in this group had higher glycated hemoglobin levels—a measure of average blood sugar over months—than those in the concordant, lower-risk profile.
The researchers then tested whether adding these profile assignments improved predictions of major adverse cardiac events compared to SCORE2, the standard cardiovascular risk calculator recommended by the European Society of Cardiology. The answer was nuanced. The new model did improve predictions, but selectively. In the KUL cohort, it enhanced prediction of heart events in men. In the SIDIAP cohort, it improved MACE prediction for men and extended MACE prediction for women. Retinopathy—diabetic eye damage—was better predicted in men from one cohort and women from another. The gains were real but not universal across all groups and outcomes.
When researchers applied a decision curve analysis—a method that weighs the practical benefit of correctly identifying high-risk patients against the cost of unnecessary interventions—the model showed its value. At a 10 percent risk threshold for heart events over ten years, the new approach identified four additional people who genuinely needed treatment while avoiding 37 unnecessary interventions per 10,000 tested. For type 1 diabetes patients specifically, the numbers shifted: two additional correct interventions while avoiding 5,746 unnecessary ones per 10,000 tested in the male SIDIAP subgroup. Those avoided interventions matter—they represent people spared from medications and monitoring they did not need.
The mechanism behind these improvements traces to specific biomarkers. Fasting glucose levels differed between profiles in both men and women. Systolic blood pressure divergence appeared in women; LDL cholesterol differences in men. These become targets for prevention. The researchers note that chronic high blood sugar in type 1 diabetes may actually obscure other cardiovascular risk factors, making the disease harder to stratify using conventional methods. Patients with good glucose control may follow entirely different pathways to heart disease than those with poor control.
The practical advantage is substantial: the model uses only routine clinical measurements—the same biomarkers doctors already collect—plus waist-to-hip ratio, which takes seconds to obtain. No specialized testing. No added burden on healthcare systems. The tool is already available as a digital application that could integrate into electronic health records, making it accessible to clinicians in real practice.
Limitations remain. The study used cross-sectional data—a snapshot in time—rather than following patients over years to see how their risk profiles shift. European data also limits how well the findings apply globally. Future work will need to track whether these phenotypes remain stable or evolve, and whether the model holds up in other populations. But the core finding stands: type 1 diabetes creates a distinct cardiovascular risk landscape that standard tools miss, and a more granular approach to profiling can help clinicians catch complications earlier and intervene more precisely.
Citações Notáveis
Chronic hyperglycemia in type 1 diabetes may mask other relevant cardiovascular risk factors and profiles, making risk stratification more difficult— Study authors
Quer a matéria completa?
Leia o original em News-Medical.net ↗
Health & Medicine